The payments company is building on a flurry of innovations unveiled in early 2024. A buy-the-dip approach is bolstering the chip maker as individual investors position for its shares to rally.

Hims & Hers (HIMS) stock is sinking 20% today after Eli Lilly (LLY) unveiled significantly cheaper versions of its popular ...

Organovo Holdings, Inc. (Nasdaq:ONVO) ("Organovo" or the "Company"), a clinical stage biotechnology company focused on developing novel treatment approaches ...

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity ...

Lilly expands its Zepbound vial offering, as HIMS pulls back on semaglutide, and other biotech news in today's Readout ...

Eli Lilly & Co. said Tuesday that it has launched new doses of its obesity treatment drug and reduced its prices. The ...

Eli Lilly has cut the price for vials of its weight-loss drug Zepbound sold online and expanded the range of doses in an ...

The pharmaceutical company said it has launched 7.5 and 10 milligram single-dose vials of its Zepbound drug, also known as tirzepatide, which join the existing lineup of 2.5 and 5 milligram vials.

Eli Lilly stock surges past $840, outperforming the S&P 500. Click here to learn why LLY stock is still undervalued and why ...

We recently compiled a list of the 20 High Growth Mega Cap Stocks You Can Buy And Hold For Next 5 Years. In this article, we ...

Eli Lilly is offering higher-dose vials through its direct-to-consumer website, LillyDirect, which started offering lower ...

Eli Lilly (LLY) stock in focus as the company expands Zepbound offerings with new vial formats at discounted prices. Read ...